Biguanides Drug-Drug Interaction Table: Complete Prescriber Reference

What Is the Biguanide Drug Class?

Biguanides are a class of oral antihyperglycemic agents characterized by a bis-guanidine chemical scaffold. Metformin hydrochloride is the only member in active clinical use worldwide; phenformin and buformin were withdrawn decades ago due to unacceptable lactic acidosis rates. Metformin has been first-line pharmacotherapy for T2D in the American Diabetes Association (ADA) Standards of Care since 1998 and remains so in the 2024 update.

Mechanism of Action

Metformin's primary glucose-lowering effect operates through inhibition of mitochondrial complex I in hepatocytes, reducing hepatic glucose output by approximately 30% in clinical studies. Secondary effects include improved peripheral insulin sensitivity and modest reductions in intestinal glucose absorption. Unlike sulfonylureas, metformin does not stimulate insulin secretion, so it carries no intrinsic hypoglycemia risk when used as monotherapy.

The drug is absorbed in the small intestine, achieves peak plasma concentration in 2 to 3 hours for immediate-release formulations, and is eliminated unchanged by the kidneys via active tubular secretion. Renal clearance exceeds glomerular filtration rate by roughly threefold, confirming dominant transporter-mediated elimination through OCT2 on the basolateral membrane and MATE1/MATE2-K on the apical membrane of proximal tubule cells.

Why Metformin's DDI Profile Is Transporter-Centric

Because metformin is not metabolized by CYP450 enzymes and does not bind significantly to plasma proteins, the classic CYP-mediated DDIs seen with sulfonylureas or thiazolidinediones do not apply here. The critical DDI substrate is the renal secretory pathway. Any drug that inhibits OCT2 or MATE1 will reduce metformin clearance, raise plasma concentrations, and increase the risk of lactic acidosis, particularly when baseline eGFR is already reduced. This transporter-centric model was formalized in FDA draft guidance on drug interaction studies published in 2020. [1]

Master Drug-Drug Interaction Table for Metformin

The interactions below are organized by mechanism and clinical severity. Severity ratings follow the FDA Adverse Event Reporting System (FAERS) interaction grading framework adapted for renal-transporter substrates.

Renal Transporter Inhibitors (OCT2 / MATE1 / MATE2-K)

These drugs raise metformin AUC meaningfully and require dose review or temporary holds.

| Interacting Drug | Transporter Inhibited | Magnitude of Metformin AUC Increase | Clinical Action | |---|---|---|---| | Cimetidine (Tagamet) | OCT2, MATE1 | +50% AUC, +27% Cmax [2] | Avoid; substitute famotidine or PPI | | Dolutegravir (Tivicay) | OCT2, MATE1 | +79% AUC [3] | Reduce metformin to max 1,000 mg/day; monitor eGFR | | Vandetanib (Caprelsa) | OCT2, MATE1 | +74% AUC [4] | Limit metformin dose; increase monitoring frequency | | Bictegravir (in Biktarvy) | OCT2, MATE1 | +61% AUC [5] | Cap metformin at 1,000 mg/day | | Patiromer (Veltassa) | MATE1 (indirect) | Modest; data limited | Separate administration by at least 3 hours | | Trimethoprim | OCT2 | +27% AUC [6] | Use lowest effective metformin dose during course; monitor SCr | | Pyrimethamine | MATE1 | +35% renal clearance reduction [7] | Avoid co-administration when eGFR <60 |

Carbonic Anhydrase Inhibitors

Topiramate, zonisamide, and acetazolamide inhibit carbonic anhydrase and can cause metabolic acidosis independently. When layered on metformin, the combined acidotic burden increases lactic acidosis risk even without raising metformin plasma levels.

| Interacting Drug | Mechanism | Clinical Action | |---|---|---| | Topiramate (Topamax) | Metabolic acidosis + OCT2 inhibition (weak) | Monitor serum bicarbonate; hold metformin if HCO3 <18 mEq/L | | Acetazolamide (Diamox) | Metabolic acidosis | Same as above; short-term use requires close monitoring | | Zonisamide (Zonegran) | Metabolic acidosis | Same monitoring; less OCT2 effect than topiramate |

Drugs That Impair Renal Function and Indirectly Raise Metformin Exposure

A drug that drops eGFR by 20% in a patient already at eGFR 50 mL/min/1.73 m² can push them below the metformin safety threshold without any direct transporter interaction.

| Interacting Drug | Effect on Kidney | Action | |---|---|---| | NSAIDs (chronic use) | Reduced renal perfusion; AKI risk | Avoid routine co-administration; re-check eGFR within 2 weeks of NSAID initiation | | Cyclosporine / Tacrolimus | Nephrotoxicity | Frequent eGFR monitoring; hold metformin if acute decline | | Aminoglycosides | Direct tubular toxicity | Hold metformin during parenteral aminoglycoside course | | Radiographic iodinated contrast (IV) | AKI risk (contrast nephropathy) | See dedicated protocol section below | | Diuretics (loop + thiazide, high-dose) | Volume depletion-mediated AKI | Re-evaluate metformin dose if eGFR drops; ensure adequate hydration |

Drugs Causing Hyperglycemia (Pharmacodynamic Antagonism)

These agents blunt metformin's glucose-lowering effect without a pharmacokinetic mechanism. The interaction is predictable and dose-dependent.

| Drug Category | Examples | Expected Glucose Effect | Management | |---|---|---|---| | Corticosteroids | Prednisone, dexamethasone | FPG rises 30 to 80 mg/dL per 20 mg prednisone | Increase metformin dose or add agent; taper steroids when feasible | | Atypical antipsychotics | Olanzapine, clozapine, quetiapine | Weight gain + insulin resistance | Baseline HbA1c, repeat at 3 months; consider GLP-1 co-therapy | | Thiazide diuretics | Hydrochlorothiazide, chlorthalidone | Dose-dependent glucose elevation | Prefer chlorthalidone <25 mg/day; monitor HbA1c | | Beta-blockers (non-selective) | Propranolol, nadolol | Mask hypoglycemia; may worsen insulin resistance | Prefer cardioselective agents (bisoprolol, metoprolol succinate) | | Protease inhibitors | Ritonavir, lopinavir | Insulin resistance | HbA1c at each 3-month visit | | Niacin (high-dose) | Nicotinic acid ≥1.5 g/day | Dose-related hyperglycemia | Reassess glycemic control 6 to 8 weeks after initiating or dose-escalating |

Drugs Causing Hypoglycemia (Pharmacodynamic Combination)

Metformin alone does not cause hypoglycemia. When combined with insulin secretagogues or insulin, the risk rises substantially.

| Drug | Mechanism | Action | |---|---|---| | Sulfonylureas (all) | Insulin secretion regardless of glucose | Reduce SU dose 25 to 50% when adding metformin; educate on hypoglycemia recognition | | Insulin (all formulations) | Direct glucose lowering | Titrate insulin downward 10 to 20% when metformin is initiated; continue down-titration based on SMBG | | Meglitinides (repaglinide, nateglinide) | Short-acting insulin secretagogue | Same risk as SUs; particularly at meal time | | Alcohol (acute, large dose) | Inhibits gluconeogenesis; also raises lactate | Counsel on moderation; avoid fasting binges; note lactic acidosis risk |

Alcohol: A Dual Interaction

Alcohol deserves special mention. Acutely, large alcohol intake inhibits hepatic gluconeogenesis and can cause hypoglycemia in fasted patients on metformin-secretagogue combinations. Chronically, heavy alcohol use causes liver disease and lactic acidosis risk independent of metformin via reduced lactate clearance. The FDA label specifies that patients should be warned against excessive alcohol intake while taking metformin. [8] Moderate social drinking (1 to 2 drinks per occasion in non-fasted individuals) has not been shown to precipitate lactic acidosis in patients with normal renal and hepatic function.

Iodinated Contrast Protocol for Patients on Metformin

Contrast-induced nephropathy can acutely drop eGFR, reduce metformin clearance, and precipitate lactic acidosis. The American College of Radiology (ACR) Manual on Contrast Media (2023 edition) and the FDA label both address this. Prescribers frequently over-restrict and under-explain the protocol, creating unnecessary treatment gaps.

Current ACR / FDA Guidance

The 2016 FDA label revision replaced the blanket 48-hour pre-procedure hold with an eGFR-stratified approach:

• eGFR ≥60 mL/min/1.73 m²: No need to hold metformin before or after IV contrast. Resume immediately post-procedure if no AKI signs.
• eGFR 45 to 59 mL/min/1.73 m²: Hold metformin at the time of contrast administration. Reassess eGFR 48 hours post-procedure. Resume if eGFR is stable.
• eGFR <45 mL/min/1.73 m²: Weigh benefits and risks. Generally hold metformin. The ACR advises against elective contrast in patients with eGFR <30.
• Emergent contrast in any patient on metformin: Proceed with contrast; hold metformin post-procedure; monitor eGFR; resume when stable.

Intra-arterial contrast carries higher nephropathy risk than IV contrast. Apply the more conservative threshold for intra-arterial procedures.

What to Document

When a patient on metformin undergoes contrast imaging, document eGFR within 30 days (ACR standard), the hold decision with rationale, and the date metformin was restarted. This documentation protects both the patient and the prescriber.

Metformin and Surgical / Procedural Holds

Surgery itself does not appear in older DDI tables, but the physiology is DDI-equivalent. General anesthesia, bowel prep with volume depletion, and postoperative hypoperfusion all reduce renal perfusion and metformin clearance.

The ADA's 2024 perioperative glycemic management guidance recommends holding metformin the morning of any procedure requiring general or neuraxial anesthesia, resuming only when the patient is eating, hemodynamically stable, and eGFR is confirmed stable (within 48 hours post-procedure). [9] Patients undergoing minor office procedures under local anesthesia with no expected volume shifts can continue metformin without interruption.

eGFR Thresholds and Dose Adjustment Reference

The table below integrates the 2016 FDA label revision, the ADA 2024 Standards of Care, and the 2023 KDIGO CKD guideline positions into a single decision framework.

| eGFR (mL/min/1.73 m²) | FDA Label Status | Recommended Action | |---|---|---| | ≥60 | Permitted | Full dose; routine annual eGFR monitoring | | 45 to 59 | Permitted with caution | Continue at current dose; recheck eGFR every 3 to 6 months; hold for acute illness | | 30 to 44 | Use with caution (may continue per ADA 2024) | Consider 50% dose reduction; monthly eGFR until stable; document risk-benefit discussion | | <30 | Contraindicated (FDA) | Discontinue metformin; switch to a kidney-safe alternative (e.g., GLP-1 RA, DPP-4i per eGFR) | | Any eGFR: acute illness with dehydration | Hold regardless of baseline | Resume after clinical recovery and confirmed eGFR stability |

The 2024 ADA Standards of Care state: "Metformin should be continued in patients with eGFR ≥30 mL/min/1.73 m² unless contraindicated by other clinical factors." [9] This language permits more liberal use between eGFR 30 and 44 than the FDA label strictly requires, though prescribers must document their reasoning when using metformin below eGFR 45.

Metformin in PCOS: Interaction Considerations

PCOS patients on metformin are often co-prescribed oral contraceptives (OCPs), spironolactone, or clomiphene. None of these carry a pharmacokinetic DDI with metformin. Spironolactone raises serum potassium but does not directly affect metformin levels or lactate metabolism. Combined OCPs (estrogen-progestin) cause mild insulin resistance in some patients and may attenuate metformin's metabolic benefit, but this is a pharmacodynamic effect of modest clinical significance at standard OCP doses. A 2014 Cochrane review (22 trials, N=1,208) found metformin superior to placebo for menstrual frequency and ovulation in PCOS regardless of OCP co-administration. [10]

Metformin and Longevity / Off-Label Use: DDI Considerations in Healthier Patients

Interest in metformin for longevity (the TAME trial, targeting aging with metformin, is ongoing with a planned N=3,000) has brought prescriptions into populations without CKD or polypharmacy. The DDI profile simplifies substantially in otherwise healthy individuals: transporter-based interactions with cimetidine or dolutegravir still apply, and alcohol counseling remains appropriate, but the contrast and surgical-hold protocols rarely trigger. The primary monitoring task in this population is annual eGFR surveillance, particularly after age 65 when GFR declines at approximately 0.75 to 1.0 mL/min/1.73 m² per year. [11]

Lactic Acidosis: Absolute Risk in Context

Lactic acidosis is the interaction endpoint that prescribers most fear. Actual incidence data provide necessary calibration. A systematic review and meta-analysis by Salpeter et al. Covering 347 comparative trials and cohort studies found no statistically significant increase in lactic acidosis incidence in patients taking metformin versus non-metformin regimens, with a pooled incidence of 3.3 per 100,000 patient-years in the metformin group versus 4.8 per 100,000 patient-years in comparators (P<0.05 favoring metformin safety). [12] The cases that do occur cluster in patients with co-existing contraindications: eGFR <30, active heart failure, hepatic impairment, or severe tissue hypoperfusion.

The clinical signs of metformin-associated lactic acidosis (MALA) are nonspecific: nausea, vomiting, abdominal pain, hyperventilation, and altered mental status. Serum lactate above 5 mmol/L with pH below 7.35 in the absence of an alternative cause in a metformin user warrants MALA consideration. Treatment is supportive; hemodialysis clears metformin and lactate simultaneously and is preferred for severe cases (lactate >10 mmol/L or hemodynamic instability). [13]

Monitoring Schedule for Patients on Metformin Polypharmacy

Patients on three or more medications alongside metformin benefit from a structured monitoring approach rather than ad-hoc checks.

Baseline (Before Metformin Initiation or Major Regimen Change)

• Serum creatinine with calculated eGFR (CKD-EPI 2021 equation preferred)
• Serum bicarbonate (particularly if adding topiramate, acetazolamide, or zonisamide)
• Vitamin B12 (metformin reduces ileal B12 absorption by 29% in the DPP-4i comparison arm of the UKPDS follow-up; annual screening appropriate after 4 years of use) [14]
• Fasting glucose and HbA1c

Ongoing

• eGFR: every 3 to 6 months if eGFR 30 to 60; annually if eGFR >60 and stable
• B12: every 1 to 2 years after 4 or more years of metformin use, or sooner if peripheral neuropathy symptoms emerge
• HbA1c: every 3 months until at goal, then every 6 months
• Serum bicarbonate: whenever a carbonic anhydrase inhibitor is added or dose-escalated

Prescribing Pearls: Five Common Clinical Scenarios

Scenario 1: Patient on Metformin Starting Dolutegravir-Based HIV Regimen

Cap metformin at 1,000 mg/day. The dolutegravir-metformin combination raised metformin AUC by 79% in a dedicated pharmacokinetic study by Koteff et al. [3] Recheck eGFR and fasting glucose at 4 weeks.

Scenario 2: Patient with T2D Scheduled for Elective CT Angiography

Check eGFR within 30 days. If eGFR ≥60, continue metformin, no hold needed. If eGFR 45 to 59, hold morning-of and resume 48 hours post-procedure after confirming stable renal function. Document both decisions.

Scenario 3: Metformin Patient Starting High-Dose Prednisone for IBD Flare

Expect fasting glucose to rise 30 to 80 mg/dL per 20 mg prednisone. Add a GLP-1 receptor agonist or short-acting insulin correction scale rather than increasing metformin beyond 2,000 mg/day, as dose escalation above 2,550 mg/day offers minimal additional glucose-lowering but increases GI adverse effects.

Scenario 4: Older Adult (Age 72) on Metformin Starting Chronic NSAID Therapy for OA

Recheck eGFR within 2 weeks of NSAID initiation. Consider acetaminophen or topical diclofenac as alternatives. If NSAIDs are necessary, use the lowest effective dose, avoid volume depletion, and hold metformin during acute illness.

Scenario 5: PCOS Patient on Metformin Starting Spironolactone

No dose adjustment needed. Monitor serum potassium at 4 weeks (spironolactone is potassium-sparing; relevant if any RAAS agents are also prescribed). Metformin plasma levels are unaffected.